This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis of the 6'-Fluoro Derivatives of Carbocyclic 2',3'-Dideoxy-3'-oxa-adenosine

Steve Tam^a; Michael Holman^a; Donna Huryn^a; Andrew Cislo^a Roche Research Center, Hoffmann La-Roche Inc., Nutley, NJ

 $\label{thm:continuous} \textbf{To cite this Article Tam}, Steve \ , Holman, Michael \ , Huryn, Donna \ and Cislo, Andrew (1991) \ 'Synthesis of the 6'-Fluoro Derivatives of Carbocyclic 2',3'-Dideoxy-3'-oxa-adenosine', Nucleosides, Nucleotides and Nucleic Acids, 10: 1, 245 <math display="inline">-$ 248

To link to this Article: DOI: 10.1080/07328319108046452

URL: http://dx.doi.org/10.1080/07328319108046452

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF THE 6'-FLUORO DERIVATIVES OF CARBOCYCLIC 2',3'-DIDEOXY-3'-OXA-ADENOSINE

Steve Tam*, Michael Holman, Donna Huryn and Andrew Cislo

Roche Research Center, Hoffmann La-Roche Inc., Nutley, NJ

ABSTRACT. Different strategies for the synthesis of the 6'- α and β -fluoro derivatives of carbocyclic 2',3'-dideoxy-3'-oxa-adenosine are described.

Although a diversity of structures have shown in-vitro antiretroviral activity against Human Immunodeficiency Virus (HIV), 1 the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS), 2'3'-dideoxynucleosides are the only class of compounds that have demonstrated activity in humans. $^{3-5}$ Besides 3'-azido-3'-deoxythymidine (AZT), the first drug approved for the treatment of patients with AIDS and ARC (AIDS-related Complex), both 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) have been granted an expanded access through an "open-label safety protocol" while they are undergoing advanced clinical evaluations. To date, these three drugs represent the best hope for people inflicted with this terrible disease. However, the use of these drugs is often hampered by their dose-limiting side effects. Taken together with the emergence of AZT-resistant mutant viruses, 6 the situation clearly calls for better therapeutic agents for the treatment of AIDS and the less severe stages of HIV infection.

As part of our anti-HIV program, we have prepared a novel series of carbocyclic 2',3'-dideoxy-3'-oxa-nucleosides which can be exemplified by structure 1.7 These compounds were designed to be resistant to acid-mediated degradation, thus eliminating one major catabolic pathway of 2',3'-dideoxynucleosides, particularly those with the purine bases such as ddI and ddA. The adenine analog (1) was found

TAM ET AL.

R = protected form of 5'-CH₂O H X = OH or OTf

SCHEME 1

SCHEME 2

SCHEME 3

to exhibit anti-HIV activity in CD4+ cells as well as in human peripheral blood T4 cells, and to be substantially more resistant to degradation by acid, adenosine deaminase and purine nucleoside phosphorylase than ddA.⁸ These encouraging results prompted us to explore the synthesis of the 6'-fluoro derivatives, 2 and 3.

Two initial approaches to the 6'- β -fluoro compound 2 involved elaboration of key intermediates 4 and 5 (SCHEME 1). However, attempts to perform SN2 type displacements on the leaving groups in 4 and 5 were not successful. The target compound was eventually obtained via the azide intermediate 11, followed by reduction and elaboration of the adenine ring 9 on the NH2 group in 12 (SCHEME 2).

Interestingly, contrary to the above findings, synthesis of the 6'- α -fluoro compound ${\bf 3}$ can be accomplished either through a direct displacement of the tosyl group in the fluoro compound 18 with adenine (SCHEME 3) or by a reaction of the 6'- β -OH nucleoside **24** with DAST (SCHEME 4). intermediate 18 was prepared as shown; however, the compound was unexpectedly unstable thus rendering this synthesis Synthesis of the β -OH isomer 24 unsuitable for scale-up. originally involved inversion at the C-6' center of 20. Unfortunately, the product obtained after an oxidationreduction sequence was found to have epimerized at C-1'. Consequently, we turned to the alternative sequence shown in SCHEME 4. Ring opening of the 6'-8-anhydro-nucleoside 22 with H2S/pridine followed by a catalytic reduction of the SH group gave a moderate yield of the 6'- β -OH compound 24 which was then converted to 3.

TAM ET AL.

SCHEME 4

REFERENCES

- 1 Polsky, B. Rev. Infectious Diseases 1989, 2, S1648.
- 2. Gallo, R.C. *J. AIDS* **1988**, 521.
- Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R.T.; Jackson, G.G.; Durack, D.T.; King, D. New Eng. J. Med. 1987, 317, 185
- 4. Yarchoan, R.; Perno, C.F.; Thomas, R.V.; Klecker, R.W.; Allain, J.-P.; Wills, R.J.; McAtee, N.; Fischl, M.A.; Dubinsky, R.; McNeely, M.C.; Mitsuya, H.; Pluda, J.M.; Lawley, T.J.; Leuther, M.; Safai, B.; Collins, J.M.; Myers, C.E.; Broder, S. Lancet 1988, 1, 76.
- Lambert, J.S.; Seidlin, M.; Reichman R.C.; Plank, C.S.; Laverty, M.; Morse, G.D.; Knupp, C.; McLaren, C.; Pettinelli, C.; Valentine, F.T.; Dolin, R. New Eng. J. Med. 1990, 322, 1333.
- Larder, B.A.; Darby, G.; Richman, D.D. Science 1989, 243, 1731.
- 7. Huryn, D.M.; Sluboski, B.C.; Tam, S.Y.; Todaro, L.J.; Weigele, M. Tetrahedron Lett. 1989, 30, 6259.
- 8. Frank, K.B.; Connell, E.V.; Holman, M.J.; Huryn, D.M.; Sluboski, B.C.; Tam, S.Y.; Todaro, L.J.; Weigele, M.; Richman, D.D.; Mitsuya, H.; Broder, S.; Sim, I.S. Ann. N.Y. Acad. Sci. In press.
- Shealy, Y.F., Clayton, J.D. J. Amer. Chem. Soc. 1969, 91, 3075.